Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19356243 | 0.89 | HTT (0.60) | MAPTHTTGFERSMN1; SMN2ALDH1A1 | |
| SCHEMBL11304999 | 0.89 | HTT (0.60) | MAPTHTTGFERSMN1; SMN2ALDH1A1 | |
| SCHEMBL15651281 | 0.86 | HTT (0.79) | MAPTHTTGFERSMN1; SMN2ALDH1A1 | |
| SCHEMBL10668207 | 0.85 | MAPT (0.58) | MAPTHTTGFERSMN1; SMN2HPGD | |
| SCHEMBL5086751 | 0.82 | MAPT (0.56) | MAPTHTTGFERSMN1; SMN2ALDH1A1 | |
| SCHEMBL9321597 | 0.77 | MAPT (1.00) | MAPTGFERSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2747321 | 0.77 | MAPT (0.68) | MAPTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL10668247 | 0.77 | KCNJ1 (0.51) | MAPTSMN1; SMN2ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL520418 | 0.77 | POLB (0.63) | MAPTSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL29531076 | 0.77 | POLB (0.63) | MAPTSMN1; SMN2ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | MAPT 2615/4885HTT 3145/4885GFER 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.